8:40 AM - 8:41 AM
○Tetsuro OHMORI (Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan)
[AsCNP] Symposium
AsCNP » [AsCNP] Symposium
Sat. Oct 12, 2019 8:40 AM - 10:20 AM Room 11 (502)
Organizer / Chair: Tetsuro OHMORI (Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan), Co-chair: Yasunori MORIO (Translational Medical Center, National Center of Neurology and Psychiatry, Japan), Discussants: Kotaro HATTORI (Medical Genome Center, National Center of Neurology and Psychiatry, Japan), Tetsurou KIKUCHI (New Drug Research Division, Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd., Japan)
Schizophrenia is a complex psychiatric disorder with a lifetime morbidity rate of 0.5 ―1.0%. Despite the etiological complexities of schizophrenia, accumulating evidence suggests that glutamatergic disturbances, inflammation, and alterations in one-carbon metabolism might play key roles in the pathophysiologies of schizophrenia, which in turn helps us identify novel therapeutic targets. In this session, we will present our latest preclinical and human research findings to discuss novel therapeutic strategies for treatment of schizophrenia and associated psychiatric conditions.
8:40 AM - 8:41 AM
○Tetsuro OHMORI (Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan)
8:41 AM - 9:01 AM
○Atsushi KAMIYA (Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, USA)
9:01 AM - 9:21 AM
○Akihito UEZATO (School of Health and Welfare, International University of Health and Welfare, Japan)
9:21 AM - 9:41 AM
○Shusuke NUMATA (Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, Japan)
9:41 AM - 10:01 AM
○Kazutaka OHI1, 2 (1. Department of Neuropsychiatry, Kanazawa Medical University, Japan, 2. Medical Research Institute, Kanazawa Medical University, Japan)
10:01 AM - 10:19 AM
10:19 AM - 10:20 AM